This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
by Zacks Equity Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health
by Kinjel Shah
Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.
The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals
by Zacks Equity Research
Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.
Top Stock Reports for Coca-Cola, Merck & Toyota Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
by Zacks Equity Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
by Zacks Equity Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), given its better-than-expected earnings and strategic alliances.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
by Zacks Equity Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
by Zacks Equity Research
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
The Zacks Analyst Blog Highlights Coca-Cola, Home Depot, Merck and JPMorgan Chase
by Zacks Equity Research
Coca-Cola, Home Depot, Merck and JPMorgan Chase are part of Zacks Top Analyst Blog.
3 Large-Cap Stocks up More Than 20% Year-To-Date
by Derek Lewis
All three sport strong Zacks Ranks - a significant perk that instills confidence in these companies' share performances moving forward.
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
by Zacks Equity Research
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Buy These 4 Blue-Chip Stocks to Strengthen Your Portfolio
by Nalak Das
We have narrowed our search to four Dow stocks. These are: HD, KO, MRK and JPM.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $93.01 in the latest trading session, marking a -0.13% move from the prior day.
Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ
by Zacks Equity Research
Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
by Zacks Equity Research
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Roche's (RHHBY) Lunsumio Application Gets Priority Review
by Zacks Equity Research
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.